TORONTO, ONTARIO--(Marketwired - Sept. 12, 2017) - Arch Biopartners Inc., (Arch or the Company) (TSX VENTURE:ARCH)(OTCBB:ACHFF), announced today it has increased the size of the non-brokered private placement the Company previously announced in a press release August 10, 2017, from $155,000 to $200,000 (the "Offering").

TORONTO, ONTARIO--(Marketwired - July 27, 2017) - Arch Biopartners, Inc., (Arch or the Company) (TSX VENTURE:ARCH)(OTCBB:ACHFF) today provided an update on the progress of the good manufacturing practice (GMP) production campaign for AB569, the Company's inhalation drug candidate for treating antibiotic-resistant bacterial infections in the lungs of cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) patients.

TORONTO, ONTARIO--(Marketwired - July 24, 2017) - Arch Biopartners Inc., (Arch or the Company) (TSX VENTURE:ARCH)(OTCBB:ACHFF) announced today it has retained Mackie Research Capital Corporation ("Mackie Research") to provide market-making services to the Company in compliance with, and subject to, the policies, guidelines and approval of the TSX Venture Exchange and other applicable legislation.